Banca de DEFESA: ANTONIO ALVES DE SOUZA NETO

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : ANTONIO ALVES DE SOUZA NETO
DATE: 01/09/2025
TIME: 16:00
LOCAL: Sala de reunião da GEP
TITLE:

Efficacy and safety of human papillomavirus vaccination in patients with human immunodeficiency virus: an overview and network meta-analysis overview

KEY WORDS:

Papillomavirus vaccines; Vaccine efficacy; HIV.

PAGES: 90
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

Introduction: Human papillomavirus (HPV) is the most common sexually transmitted infection and is associated with cancers of the penis, cervix, vulva, vagina, and oropharynx. Prophylactic HPV vaccines offer protection against high-risk HPV types and have been proven effective for 14 years. Although these vaccines are generally safe and effective, their efficacy and safety in People Living with Human Immunodeficiency Virus (PLHIV) remain uncertain, despite the elevated risk of HPV-related cancers in this population. Objective: This review aims to evaluate the efficacy and safety of HPV vaccination in PLHIV. Methods: The overview was developed according to the Preferred Reporting Items for Systematic Reviews and Incorporating Network Meta-Analyses (PRISMA-NMA). An electronic search without date or language restrictions was conducted in several databases using keywords related to HPV vaccines, efficacy, and safety. We included systematic reviews of randomized controlled trials (RCTs) involving people living with HIV who received bivalent (bHPV), quadrivalent (qHPV), or nonavalent (9vHPV) HPV vaccines. Study selection (Rayyan software) and data extraction were conducted by two independent researchers, and discrepancies were resolved by a third author. Quantitative synthesis was performed using R software. Risk of bias was assessed using AMSTAR 2. The certainty of the evidence was assessed using CINeMA. Results: Network meta-analysis identified that the qHPV vaccine showed significant immunological efficacy, with a significant increase in seroconversion for anti-HPV 6 (OR: 17.72; 95% CI: 2.55, 123.19) and anti-HPV 18 (OR: 22.81; 95% CI: 2.31, 225.32) antibodies, compared to the control group. No significant differences were observed for types 11 and 16. Regarding safety, qHPV demonstrated the best profile regarding pain outcomes at all doses analyzed, with a p-score greater than 0.98. Conclusions: The qHPV vaccine presented the best safety profile regarding pain, including at all doses. Regarding immunological efficacy, significant differences were only found between patients vaccinated with qHPV for Anti-HPV 6 and 18.

COMMITTEE MEMBERS:
Externo à Instituição - EDILMAR DE MOURA SANTOS
Presidente - 3313589 - JANAINA CRISTIANA DE OLIVEIRA CRISPIM FREITAS
Externa ao Programa - 4149590 - MARIA DE LOURDES COSTA DA SILVA - null